Month: May 2024

Company announcement – No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter.Strong topline results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASHPDUFA date for glepaglutide in SBS set by US FDA for December 22, 2024PDUFA date for dasiglucagon in CHI for up to three weeks of dosing (Part 1 of NDA) set by US FDA for October 8, 2024Cash runway extended into 2027 through private placement of shares to institutional investors in January 2024 for gross proceeds of DKK 1.45 billionCopenhagen, Denmark, May 16, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery...

VEON 1Q24 Trading Update: Accelerating USD Growth, Strong Operational Execution Amsterdam, 16 May 2024 07:00AM CEST – VEON Q1 2024 HighlightsQ1 revenue of USD 942 million, +6.6% YoY (+11.6% YoY in local currency) and EBITDA of USD 386 million, +0.2% YoY (+5.1% YoY in local currency) Q1 capex of USD 125 million, +38.6% YoY, with LTM capex intensity of 18.3% Total cash and cash equivalents of USD 632 million, with USD 261 million at HQ; and gross debt at USD 3.7 billion (decreased by USD 2.0 billion YoY), with net debt excluding lease liabilities at USD 2.0 billion; VEON repaid its Revolving Credit Facility Maintaining FY 2024 revenue growth guidance in local currency of 16-18%, EBITDA growth guidance in local currency of 18-20%, and capex intensity of 18-19% VEON management increases share ownership; announces its 2024 Annual General...

Consolidated interim report 1 January – 31 March 2024 Company announcement no. 17 Date: 16 May 2024 Key points from Q1-24 report (period 1 January – 31 March 2024) On 16 May 2024, the Board of Directors and the Executive Management of Pharma Equity Group A/S (“PEG”, “the Company” or “the Group”) considered and approved the interim report of the Group for the period 1 January – 31 March 2024 (“Q1 2024 Report”). The report has not been audited or reviewed. Clinical results Shortly after the end of Q1, the Company’s subsidiary, Reponex Pharmaceuticals A/S (Reponex), was able to report very positive final results from Reponex’ clinical phase 2 proof-of-concept trial of the drug candidate RNX-051, the MEFO study, based on the high-level summary received from Reponex’ clinical site. Reference is made to company announcement...

(in thousands)   Q1 2024   Q1 2023 YOYChange  Total Revenues $ 4,171 $ 4,484 (7.0 %)Operating Income   73   229 (68.1 %)Income Before Provision for Taxes   149   210 (29.0 %)Net Income   91   159 (42.8 %)Gross Billings*   15,824   17,587 (10.0 %)EBITDA*   110   262 (58.0 %)Adjusted EBITDA*   128   304 (57.9 %)Pre-Corporate EBITDA*   381   548 (30.5 %)* Non-GAAP measures referenced are detailed in the disclosures at the end of this release. DALLAS, May 16, 2024 (GLOBE NEWSWIRE) — Wilhelmina International, Inc. (Nasdaq:WHLM) (“Wilhelmina” or the “Company”) today reported revenues of $4.2 million and net income of $0.1 million for the three months ended March 31, 2024, compared to revenues of $4.5 million and net income of $0.2 million for the three months ended March 31, 2023....

ATHENS, Greece, May 16, 2024 (GLOBE NEWSWIRE) — Okeanis Eco Tankers Corp. (the “Company” or “OET” or “Okeanis”) (NYSE:ECO / OSE:OET), today reported unaudited condensed financial statements for the first quarter and three-month period of 2024, which are attached to this press release. Selected Q1 2024 and Recent Highlights:Time charter equivalent (“TCE”, a non-IFRS measure*) revenue and Adjusted EBITDA (a non-IFRS measure*) of $81.0 million and $65.2 million, respectively. Adjusted profit and Adjusted earnings per share (non-IFRS measures*) for the period of $39.6 million or $1.23 per basic & diluted share. Fleetwide daily TCE rate of $63,600 per operating day; VLCC and Suezmax TCE rates of $68,800 and $56,700 per operating day, respectively. Daily vessel operating expenses (“opex”, a non-IFRS measure*) of $9,208...

Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates. Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3 2023 and improved 380 bps from the prior year. Q4 2023 Adjusted EBITDA1 loss of $1.4 million compared to a gain of $0.6 million in the previous quarter, annual improvement of $7.2 million compared to prior year. Net loss from continuing operations of $60.3 million in Q4 2023, reflecting asset impairment charges of $59.9 million. Cash and cash equivalents including restricted cash of $11.4 million at the end of 2023. Signed $9.5 million of multi-year contracts in 2023 which represent annual recurring revenue. Additional cost reductions of $1.0 million annualized were actioned in Q4 2023, resulting...

Baltic Power, Hai Long and Oneida projects continue to make construction progress TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) reported today financial results for the three months ended March 31, 2024. All dollar amounts set out herein are in thousands of Canadian dollars, unless otherwise stated. “We are off to a strong start in 2024 with first quarter results better than expected, thanks to strong winds experienced at our offshore wind facilities,” said Mike Crawley, Northland’s President and Chief Executive Officer. “Construction programs for our large offshore wind projects in Taiwan and Poland, and energy storage project in Canada, continue to progress, with major pieces of equipment continuing to arrive at all three projects, and Hai Long’s 2024 in-water installation...